135 related articles for article (PubMed ID: 38086517)
1. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.
Richey P; Funk M; Sakamoto F; Plotkin S; Ly I; Jordan J; Muzikansky A; Roberts J; Farinelli W; Levin Y; Garibyan L; Blakeley JO; Anderson RR
J Am Acad Dermatol; 2024 Apr; 90(4):767-774. PubMed ID: 38086517
[TBL] [Abstract][Full Text] [Related]
2. [Cosmetic and functional results after resection of cutaneous neurofibroma in neurofibromatosis type 1 : Operation of neurofibroma improves quality of life while having moderate complications].
Walz B; Pfefferle V; Häfner HM; Kofler L
Dermatologie (Heidelb); 2022 Dec; 74(12):961-968. PubMed ID: 37728798
[TBL] [Abstract][Full Text] [Related]
3. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
4. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
Peltonen S; Jannic A; Wolkenstein P
Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1.
Kallionpää RA; Peltonen S; Le KM; Martikkala E; Jääskeläinen M; Fazeli E; Riihilä P; Haapaniemi P; Rokka A; Salmi M; Leivo I; Peltonen J
Lab Invest; 2024 Jan; 104(1):100285. PubMed ID: 37949359
[TBL] [Abstract][Full Text] [Related]
7. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
8. Current and Emerging Imaging Techniques for Neurofibromatosis Type 1-Associated Cutaneous Neurofibromas.
Li Y; Blakeley JO; Ly I; Berman Y; Lau J; Wolkenstein P; Bergqvist C; Jia W; Milner TE; Katta N; Durkin AJ; Kennedy GT; Rowland R; Romo CG; Fleming J; Kelly KM
J Invest Dermatol; 2023 Aug; 143(8):1397-1405. PubMed ID: 37330718
[TBL] [Abstract][Full Text] [Related]
9. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
Cell Rep Methods; 2024 May; ():100772. PubMed ID: 38744290
[TBL] [Abstract][Full Text] [Related]
10. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.
Kallionpää RA; Ahramo K; Martikkala E; Fazeli E; Haapaniemi P; Rokka A; Leivo I; Harvima IT; Peltonen J; Peltonen S
Dermatology; 2022; 238(2):329-339. PubMed ID: 34237737
[TBL] [Abstract][Full Text] [Related]
11. A Clinicopathologic Study on the Role of Estrogen, Progesterone, and Their Classical and Nonclassical Receptors in Cutaneous Neurofibromas of Individuals With Neurofibromatosis 1.
Rozza-de-Menezes RE; Almeida LM; Andrade-Losso RM; de Souza Vieira G; Siqueira OHK; Brum CI; Riccardi VM; Cunha KS
Am J Clin Pathol; 2021 Apr; 155(5):738-747. PubMed ID: 33289020
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
[TBL] [Abstract][Full Text] [Related]
13. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of CO2- and Er:YAG laser ablation of multiple cutaneous neurofibromas in von Recklinghausen's disease.
Kriechbaumer LK; Susani M; Kircher SG; Distelmaier K; Happak W
Lasers Med Sci; 2014 May; 29(3):1083-91. PubMed ID: 24189926
[TBL] [Abstract][Full Text] [Related]
15. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report.
Sassi I; Bouida MA; Hasnaoui A; Zemni I; Ben Dhieb T
J Med Case Rep; 2024 Jan; 18(1):15. PubMed ID: 38216958
[TBL] [Abstract][Full Text] [Related]
16. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with
Radomska KJ; Coulpier F; Gresset A; Schmitt A; Debbiche A; Lemoine S; Wolkenstein P; Vallat JM; Charnay P; Topilko P
Cancer Discov; 2019 Jan; 9(1):130-147. PubMed ID: 30348676
[TBL] [Abstract][Full Text] [Related]
17. Management of cutaneous neurofibroma: current therapy and future directions.
Chamseddin BH; Le LQ
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i107-i116. PubMed ID: 32642736
[TBL] [Abstract][Full Text] [Related]
18. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
19. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pigmentary disorders in patients with skin of color with a novel 755 nm picosecond, Q-switched ruby, and Q-switched Nd:YAG nanosecond lasers: A retrospective photographic review.
Levin MK; Ng E; Bae YS; Brauer JA; Geronemus RG
Lasers Surg Med; 2016 Feb; 48(2):181-7. PubMed ID: 26922302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]